Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PNMT | P11086 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nordexfenfluramine SCHEMBL29390405 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL4668266 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL30081494 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL30081489 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL895637 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL29538965 | 0.98 | HTR2A (0.96) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL8412627 | 0.98 | HTR2A (0.96) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL10562287 | 0.98 | HTR2A (0.96) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL16673896 | 0.92 | HTR2A (0.84) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL16673917 | 0.92 | HTR2A (0.84) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107229-A1 | REDUCING THE ADDICTIVE LIABILITY OF OPIOID ANALGESICS BY CO- ADMINISTERING 5HT2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-12558326-B2 | Method for treating epilepsy | XENON PHARMACEUTICALS INC. (CA) | 2026-02-24 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3687576-B1 | USE OF CANNABIDIOL IN COMBINATION WITH NORFENFLURAMINE OR FENFLURAMINE IN THE TREATMENT OF EPILEPSY | JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) | 2025-09-03 | — | — | EP | claimed |
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-118873517-A | Use of cannabidiol in combination with a 5-HT2B receptor agonist | 上海柯西医药科技发展有限公司 | 2024-11-01 | — | — | CN | claimed |
| EP-0875498-A2 | Process for the production of the isomers (R) and (S)-Alpha-methyl-3-(trifluoromethyl)benzeneethanamine | Alfa Chemicals Italiana S.r.l. (IT) | 1998-11-04 | — | — | EP | claimed |
| US-5808156-A | Process for the production of the isomers (R) and (S)-α-methyl-3(trifluoromethyl)benzeneethanamine | ALFA CHEMICALS ITALIANA S.P.A. (IT) | 1998-09-15 | — | — | US | claimed |
| EP-0441160-B1 | Process for preparing levo and dextro fenfluramine | LAB MAG SPA (IT) | 1995-07-05 | — | — | EP | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| EP-0302757-A2 | Anti-emetic serotonin depleting agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-02-08 | — | — | EP | claimed |
| EP-0053175-A4 | USE OF d-FENFLURAMINE FOR THE MANUFACTURE OF A MEDICAMENT FOR MODIFYING FEEDING BEHAVIOR. | MASSACHUSETTS INST TECHNOLOGY (US) | 1982-10-07 | — | — | EP | claimed |
| EP-0053175-A1 | USE OF d-FENFLURAMINE FOR THE MANUFACTURE OF A MEDICAMENT FOR MODIFYING FEEDING BEHAVIOR. | MASSACHUSETTS INST TECHNOLOGY (US) | 1982-06-09 | — | — | EP | claimed |
| WO-1981003611-A1 | METHOD AND COMPOSITION FOR UTILIZING D-FENFLURAMINE FOR MODIFYING FEEDING BEHAVIOR | MASSACHUSETTS INST TECHNOLOGY (US) | 1981-12-24 | — | — | WO | claimed |
| US-4115587-A | TREATMENT OF ATHEROSCLEROSIS AND HYPERCHOLESTER-EMIA | A. H. ROBINS COMPANY, INC. (US) | 1978-09-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2A 14/4885HTR2B 28/4885HTR2C 42/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HTR2A 207/4885HTR2B 343/4885HTR2C 390/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2A 1/4885HTR2B 7/4885HTR2C 5/4885 |
| US-12558326-B2 | Method for treating epilepsy | PNMT, SLC6A1, CPT1B | HTR2A 239/4885HTR2B 790/4885HTR2C 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.